Stay updated on Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.3 replaces the previous v3.4.2 on the page.SummaryDifference0.1%

- Check12 days agoChange DetectedNo additions or deletions were detected; the page content appears unchanged.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedMelanoma and related topics (MedlinePlus Genetics) were added, and the site revision was updated to v3.4.2 while the prior downtime notice (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check41 days agoChange DetectedAdded a site-wide notice about government funding and operations. Updated the page to Revision: v3.4.1 and removed Revision: v3.4.0.SummaryDifference0.4%

- Check48 days agoChange DetectedGlossary display was added and QC-related metadata was updated (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). In addition, content related to Melanoma and some related topics appears removed or renamed, indicating minor UI/content adjustments.SummaryDifference0.4%

- Check55 days agoChange DetectedAdded Melanoma and related topics: MedlinePlus Genetics to the related topics section. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.